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INTRODUCTION 
Water is the most widely used substance, raw material 
or starting material in the production, processing and 
formulation of pharmaceutical products. It has unique 
chemical properties due to its polarity and hydrogen 
bonds. It is capable of dissolving or suspending many 
different compounds including contaminants that may 
represent hazards themselves or that are able to react 
with intended product substances, resulting in hazards 
to health (WHO, 2006). Therefore, there is no pure 
water in nature, as it can contain unacceptable 
contaminants including inorganic compounds, organic 
compounds, solids, gases, and microorganisms (WHO, 
2005). 
Pharmaceutical water treatment requires removing these 
contaminants from municipal drinking water to meet 
pharmacopoeial standards (Khutia et al., 2010). 
Different grades of water quality are required depending 
on the route of administration of different 
pharmaceutical products (WHO, 2006). But, water used 
as an ingredient in the formulation of pharmaceutical 
products must be either of the Purified Water (PW) type 
or must be Water for Injections (WFI). Both share 
similar specifications when it comes to chemical purity 
but differ with their microbial contamination allowed, 
which is measured by colony count and by endotoxin 
level (Khutia et al., 2010). 
Unlike other products and process ingredients, Water 
for Pharmaceutical Use (WPU) is usually drawn from a 
system on demand, and is not subject to testing and 
batch or lot release before use. Assurance of quality to 
meet the on-demand expectation is, therefore, essential. 
Additionally, certain microbiological tests may require 
incubation periods and, therefore, the results are likely 
to lag the water use. Control of the microbiological 
quality of WPU is a high priority. Avoiding biological 
contamination in water treatment system components is 
no less important than avoidance of their proliferation 
in storage and distribution. Therefore, control of the 
quality of water throughout the treatment, storage and 
distribution processes, including microbiological and 
chemical quality, is a major concern which needs 
complying with Good Manufacturing Practices (GMP) 
(WHO, 2005). 
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ABSTRACT 
Water is widely used as a raw material, ingredient, and solvent in the processing, formulation, and manufacture of 
pharmaceutical products, and assessing its quality is of paramount importance. To the best of the authors’ knowledge, there 
hasn’t been any baseline assessment made with regard to the implementation status of Good Manufacturing Practices (GMP) 
principles in water treatment systems of pharmaceutical industries in Ethiopia. Hence, to assess the level of compliance to GMP 
in water treatment systems of pharmaceutical industries in Ethiopia, a national survey was conducted in all pharmaceutical 
industries of the country. Data were collected by employing quantitative and qualitative methods. Self-administered 
questionnaires were distributed to nine pharmaceutical industries and the response rate was 8 (88.5%). According to the results, 
none of the industries had an influent and effluent total organic carbon monitoring system. Among the available storage tanks 
for purified water and water for injection, 7 (87.5%) of them were of a sanitary material. However, in 4 (50%) industries pipes 
were not made of sanitary material, purified water was not kept circulating at 70-80 oC and there were dead legs in the water 
lines. The validation results were investigated and corrective action was taken only in 1 (12.5%) of the industries. The 
compliance of the water treatment systems of most of the industries to WHO GMP principles was found to be below the 
standard in many aspects. Therefore, it is recommended that the industries should exert maximum efforts to comply with GMP 
principles. 
Keywords: Good manufacturing practices, water treatment system, pharmaceutical industry, Ethiopia, pharmaceutical water 
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WHO defines GMP as “that part of quality assurance 
which ensures that products are consistently produced 
and controlled to the quality standards appropriate to 
their intended use and as required by the marketing 
authorization” (WHO, 2003). GMP covers all aspects of 
the manufacturing process including: validated critical 
manufacturing steps; suitable premises, storage, 
transport; qualified and trained production and quality 
control personnel; adequate laboratory facilities; 
approved written procedures and instructions; records to 
show all steps of defined procedures taken; full 
traceability of a product through batch processing 
records and distribution records; and systems for recall 
and investigation of complaints (WHO, 1997). GMP 
regulations require a quality approach to manufacturing, 
enabling companies to minimize or eliminate cases of 
contamination, mix ups, or any other errors (Ziegler and 
Medgyesi, 2012).  
This study attempts to investigate the status of the water 
treatment systems of pharmaceutical manufacturing 
industries in Ethiopia regarding compliance to GMP 
principles. This will allow for critical evaluation of the 
GMP status in order to identify gaps and design 
appropriate interventions. 
METHODS 
Study design and area 
In 1993, there was only one local pharmaceutical 
manufacturing plant in Ethiopia named Ethiopian 
Pharmaceutical Manufacturing Factory which was 
owned by the government. Currently however drug 
production is being undertaken by thirteen local 
pharmaceutical manufacturing plants: One government 
owned, eleven private (not affiliated with 
multinationals) and one private (affiliated with 
multinational). Three of the factories are engaged in 
medical supplies production, one on empty gelatin 
capsule production and nine on complete product 
formulation using imported raw materials. However, 
only one of them has a certificate of competence from 
the Ethiopian Food Medicine and Healthcare 
Administration and Control Authority (FMHACA, 
2012). 
The survey was conducted to assess the implementation 
of GMP principles for water treatment systems in all 9 
pharmaceutical industries that are engaged in 
manufacturing of finished pharmaceutical products. The 
survey was done on professionals working either as 
technical managers or production managers of the 
industries. The survey employed both qualitative and 
quantitative data collection methods. The two 
approaches were arranged to complement each other 
and data were collected between March and May 2013. 
Quantitative data of the professionals working in the 
water treatment section were collected using a 
structured questionnaire adopted from WHO minimum 
GMP requirement for pharmaceutical water systems 
(WHO, 2010) while a semi-structured interview guide 
with flexible probing technique was used for the in-
depth interview. 
Data Analysis  
After data collection, each checklist was checked for 
completeness and codes were given during data 
collection. Data entry for the survey was done using 
EPI info version 7 and analyzed using SPSS version 20. 
Furthermore, data cleaning was performed to check 
missed values and any inconsistencies before the data 
were analyzed. Descriptive statistics was used to 
calculate proportions and means of respondents. 
Transcription of qualitative data was done immediately 
after data collection and analysis was handled manually. 
The data was analyzed using thematic analysis 
approach. 
Ethical Clearance 
Ethical clearance was obtained from the Ethics Review 
Board of the School of Pharmacy, College of Health 
Sciences, Addis Ababa University and permission was 
then granted from all pharmaceutical industries 
included in the study. Participants were provided with 
information regarding the purpose of the study and what 
is expected from them. They were informed that 
participation is voluntary and withdrawal from the study 
at any point is possible. Participants were assured 
anonymity and that their answers will remain 
confidential. They were also reassured that the report of 
the findings will not identify them and only the 
aggregate data will be reported. Finally informed 
consent was received from every participant. 
RESULTS AND DISCUSSION 
General Overview 
Self-administered questionnaires were distributed to all 
nine pharmaceutical industries and eight of them were 
willing to respond, with a response rate of 88.5%. Four 
of the participants were production managers, three of 
them were Quality Assurance and Quality Control 
(QA/QC) managers and one of them was factory 
manager. Their working experience in pharmaceutical 
industry ranged from 5 – 22 years with an average of 
10.15 years of experience (SD = 6.6). Four of them had 
Bachelor of Pharmacy while three of them had Master 
of Science in Pharmaceutical Sciences, and one of the 
respondents had Bachelor of Science in Chemistry.  
Four (66.7%) of industries claimed to be GMP certified. 
As shown in Table 1, all of the industries had periodic 
cleaning and sanitization program for water lines and 
hoses with adequate quality of feed water. Majority 
(87.5%) of the industries had preventive maintenance 
programs but 3 (37.5%) of them did not follow proper 
frequency of maintenance program. The study also 
showed that more than three fourth (85.7%) of the 
industries had frequent sanitization program with hot 
water after intervention for maintenance or modification 
and 7 (87.5%) industry had no periodic integrity tests 
for the filters used in distillation system (Table 1). 
Standards recommend that during a water system 
validation, consideration must be given to the quality 
and seasonal variation of the feed water. Moreover, 
schedule of routine monitoring is the best way to ensure 
a membrane system is operating under optimal 
conditions (Pahwa, 2010). In line with this standard, the 
present study indicated that all of the pharmaceutical 
industries had adequate quality of feed water with 
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conductivity and microbial contamination being their important parameters used to monitor the quality. 
 
Table 1: Distribution of items indicating general overview of water treatment systems of pharmaceutical 
industries in Ethiopia, 2013 (N=8). 
 
 
Items 
Response 
Yes; N (%) No; N (%) Not Applicable; N 
(%) 
Availability of GMP certificate 4 (66.7) 2 (33.3) - 
Schematic drawing representing the water system was shown 7 (87.5) 1 (12.5) - 
Continuous supply of source of water 8 (100) - - 
Presence of raw water storage tank 7 (87.5) 1 (12.5) - 
Presence of preventive maintenance  program that includes 
the water system 
7 (87.5) 1 (12.5) - 
Presence of periodic cleaning and sanitization program for 
water lines and hoses 
8 (100) - - 
Maintenance program was of a proper frequency 5 (62.5) 2(25.5) 1 (12.5) 
Analysis was established by current editions of official 
pharmacopoeias 
8 (100) - - 
There was frequent sanitization program with hot water after 
intervention for maintenance or modification of equipments 
6 (85.7) 1 (14.3) - 
Quality of feed water was adequate  8 (100) - - 
Presence of hydrophobic vent filter 5 (62.5) 2 (25) 1 (12.5) 
Periodic integrity tests for hydrophobic vent filter  1 (14.3) 4 (57.1) 2 (28.6) 
Presence of hydrophobic vent absolute filter in the 
distillation system 
5 (62.5) 3(37.5) - 
Periodic integrity tests for the filters used in distillation 
system 
1 (12.5) 4 (50) 3 (37.5) 
 
 
Water Treatment Approaches and Monitoring 
Systems 
The study revealed that three-fourth (75.0%) of the 
industries had a system to remove chlorine. As the raw 
water must be free from oxidation media, 
dechlorination must be carried out through the use of 
activated charcoal (AC) filters or sodium bisulfite 
(Gronwald, 2012). Nevertheless, this system was absent 
in two (25%) of the industries. Furthermore, none of the 
industries had an influent and effluent Total Organic 
Carbon (TOC) monitoring system of the AC filter 
system (Nally, 2007). Another way of monitoring the 
efficiency of the AC filter is through organic adsorption 
capacity verification systems (Nally, 2007) which was 
applicable only in three (35.7%) of the industries. Since 
adsorption capacity refers to the AC filter efficiency to 
adsorb the organic impurities, decreased adsorption 
capacity shows saturation of the filter bed by organic 
impurities which leads to increased TOC level. 
Therefore, there should be frequent replacement of the 
carbon beds to maintain water quality. The study also 
indicated that there were no organic adsorption capacity 
verification systems in 5 (62.5%) of the industries and 
only 2 (28.6%) industries have undertaken frequent 
replacement of carbon beds for AC filter (Table 2). 
To achieve the desired degree of water purification, 
water is further treated by ion exchange (IX) resin or 
Reverse Osmosis (RO) after carbon filtration (VWS, 
2005). According to the results of this study, 5 (62.5%) 
industries comply with the GMP principle of having 
frequent IX resin regeneration. Among the industries 
possessing IX treatment method, only 2 (25.0%) 
industries constitute subsequent RO treatment system 
even if it is a very cost-effective technology for the 
removal of the majority of impurities due to its 
exceptional purifying efficiency.  
To produce WFI, distillation is the only final 
purification step as part of the specification of the WFI, 
declared by the International Pharmacopoeia and the 
European Pharmacopoeia (EMEA, 2003). In consistent 
with this, 5 (62.5%) industries producing WFI use 
distillation system, of which, only 1 (12.5%) industry 
has periodic integrity tests for the filters used in the 
distillation system. This lack of the integrity test may 
have its own impact on the quality of water used for 
production of parenteral products as the integrity test is 
one of the most important monitoring systems for WFI. 
If the filter integrity test fails, the sterile filtration 
process must be rejected (Agalloco and Akers, 2008). 
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Table 2: Distribution of items indicating water treatment approaches and monitoring systems of the 
pharmaceutical manufacturing industries in Ethiopia, 2013 (N=8). 
 
Items 
Response 
Yes; N (%) No; N (%) NA; N (%) 
Presence of a system to remove chlorine 6 (75) 1 (12.5) 1 (12.5) 
Verification of organic adsorption capacity 3 (35.7) 3 (37.5) 2 (25) 
Influent and effluent TOC monitoring system - 6 (75) 2 (25) 
Frequent replacement of carbon beds 2 (28.6) 4 (57.1) 1 (14.3) 
Validated frequency for regeneration of IX resin 5 (62.5) 3 (37.5) - 
Presence of  reverse osmosis system  2 (25) 1 (12.5) 5 (62.5) 
Adequacy of the concentration of the sanitizing chemical  at all 
surfaces 
3 (42.9) 1 (14.3) 3 (42.9) 
Frequent chemical sanitization approach 4 (57.1) 1 (14.3) 2 (28.6) 
Availability of SOP for sampling all types of produced water 8 (100) - - 
Sampling procedure including validated frequency and 
sampling points 
5 (62.5) 3 (37.5) - 
Sampling point rotation 5 (62.5) 3 (37.5) - 
Availability of automatic system to prevent use of water when 
it is out of specifications 
4 (50) 4 (50) - 
Online monitoring system 7 (87.5) 1 (12.5) - 
Offline monitoring system 8 (100) - - 
Action limit of PW and WFI  is no more than 100 cfu / mL and 
10 cfu / 100mL  
5 (62.5) - 3 (37.5) 
When the action limit is exceeded, an investigation was always 
undertaken to ensure quality of the batches of product made 
with that water according to OOS plan 
5 (62.5) - 3 (37.5) 
 
 
 
According to the WHO, monitoring systems of the 
water treatment systems should include a combination 
of online and offline monitoring systems (WHO, 2005). 
The results of the study show that 7 (87.5%) of the 
industries have online monitoring system while 8 
(100%) of them have offline monitoring system (Table 
2). In addition, all of the industries, 8 (100%) 
mentioned that they have Standard Operating 
Procedures (SOP) for sampling all types of produced 
water but, 3 (37.5%) of the industries did not include 
validation frequency and sampling points in their 
sampling procedure. This could make the offline 
monitoring unreliable as the sampling may not be 
representative. The lack of online monitoring systems 
might result in parameters such as conductivity and 
other tests to peak high suddenly as stated by a 
respondent from the industry lacking online monitoring 
system. Furthermore, half of the industries 4 (50.0%) 
reported that there was no automatic system to prevent 
use of water when it is Out Of Specification (OOS). 
With regard to the WFI, the USP guidelines require a 
bacteria-count limit of 10 cfu/100 ml (Paul, 2002). 
According to the results of this study, bacterial count 
limit for PW and WFI was to the standard for 5 (62.5%) 
industries and they took in an investigation according to 
OOS when the action limit is exceeded. For WPU, there 
should be an automatic system to prevent use of water 
when it is OOS (Paul, 2002) but it was only applicable 
for 4 (50%) of the pharmaceutical industries. However, 
if there is no automatic system, there will not be 
rejection of unfit water from the system which may 
result in end product of compromised quality. The 
WHO recommends appropriate sanitary specification 
plastics and stainless steel materials for WPU systems 
and when stainless steel is used, it should be at least 
grade 316 L (WHO, 2005). In this study it has been 
found that majority (87.5%) of the industries comply 
with this specification. 
Validation, Documentation and  Record Systems 
Validation and qualification of water treatment systems 
are fundamental parts of GMP and form an integral part 
of a GMP inspection. In addition, the validation 
activities should be documented and controlled through 
the use of qualification protocols and reports, typically 
these will fall into categories including installation 
qualification (IQ), operational qualification (OQ) and 
performance qualification (PQ). A three-phase approach 
should be used to satisfy the objective of proving the 
reliability and robustness of the system in service over 
an extended period (WHO, 2010). 
According to the present study, 6 (75.0%) of the 
industries performed IQ, OQ, and PQ. The proportion 
of industries practicing sampling record for phase I, 
phase II, and phase III validation were 5 (62.5%), 3 
(42.9%), and 2 (25.0%), respectively. Industries 
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performing phase I demonstrated that the system 
operates within predetermined operating ranges and 
delivers water of the required quality, and then develop 
SOP based on demonstration. Those performing phase 
II were using SOP developed during phase I for the 
water system. Those industries which were not 
performing phase III validation had no way of checking 
the system over long period of time which considers 
seasonal variation. 
The result of validation summary records showed that 
the system was under control in 3 (42.9%) industries 
and there was SOP development initiation during 
validation in 3 (37.5%) of the industries among eight. 
Deviation from the designed criteria in qualifications 
and validation was investigated and corrective action 
was taken for deviation in only 1 (12.5%) of the 
industries, but corrective action should be taken for 
every deviation from the designed criteria in 
qualifications and validation (Larsson et al. 1997). In 
addition to this, although documentation is a key part of 
validation system, only one of the industries developed 
report of investigation.  
The results of this study showed that all of the 
industries had written procedures for the operation 
system of PW. This is an important aspect of 
documentation as SOPs are among the major documents 
required for proper function of the production system. 
The presence of written procedures for the operation 
system of PW and regeneration of IX resins were 
reported by all 8 (100%) industries. There were also 
record keeping practices for all tests undertaken by all 
of the pharmaceutical industries. This would help in 
tracing back the monitoring and quality control 
practices of the industries during production of WPU. 
The proportion of industries keeping records for all tests 
undertaken, for filter sanitization, filter replacement, 
chemical sanitization, and periodic integrity tests was 
found to be 8 (100%), 1 (14.3%), 4 (50.0%), 4 (57.1%), 
and 1 (12.5%) respectively (Table 3). 
 
Table 3: Distribution of items indicating the validation processes and documentation and record systems of 
water treatment systems of the pharmaceutical manufacturing industries in Ethiopia, 2013 (N=8). 
 
Items 
Response 
Yes; N (%) No; N (%) NA; N (%) 
Underwent IQ 6 (75) 2 (25) - 
Qualification of water system installation 5 (62.5) 3 (37.5) - 
Underwent OQ 6 (75) 2 (25) - 
Underwent PQ 6 (75) 2 (25) - 
The result of validation summary records showing the system was 
under control 
3(42.9) 3 (42.9) 1 (14.3) 
SOP development  initiation during validation 3 (37.5) 5 (62.5) - 
Investigation of deviation from the designed criteria in qualifications 
&validation 
1 (12.5) 4 (50) 3 (37.5) 
Corrective action taken for the deviation 1 (16.7) 3 (50) 2 (33.3) 
Report of investigation 1 (12.5) 3 (37.5) 3 (50) 
Documentation for all the tests undertaken 8 (100) - - 
Availability of written procedures for the operation of system of PW 8 (100) - - 
Presence of a record of sanitization of carbon filter with validated 
frequency 
1 (14.3) 5 (71.4) 1 (14.3) 
Documentation being present for filter replacement 4 (50) 3 (37.5) 1 (12.5) 
Presence of SOPs for the regeneration of Ion exchange resins 8 (100) - - 
Records were kept for regeneration of ion exchange resins 8 (100) - - 
Records being kept for the chemical sanitization 4 (57.1) - 3 (42.9) 
Presence of  a record for the sanitation of PW storage and 
distribution system 
7 (87.5) 1 (12.5) 1 (12.5) 
periodic integrity test records being kept 1 (12.5) 3 (37.5) 4 (50) 
 
 
Storage Practice and Distribution System 
The study showed that all 8 (100%) of the 
pharmaceutical industries had a tank for PW storage 
while the presence of storage tanks for WFI was only 5 
(62.5%). Among the available storage tanks, 7 (87.5%) 
of them were of a sanitary material (Table 4). With 
regard to the distribution system of the water treatment 
systems, 4 (50%) industries had pipes which were not 
made of sanitary material, the PW was not kept 
circulating at 70-80 
o
C and there were dead legs in the 
water distribution lines and the temperature was not 
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maintained at 70-80 
0
C in 4 (50%) of the industries. 
This may disrupt quality of the water as stagnant waters 
with no circulations and water at low temperature are 
more susceptible to microbial proliferation (WHO, 
2010). Moreover, the pipes used in the distribution of 
WFI were ensuring delivery of the water up to the point 
of use in 5 (62.5%) industries (Table 4). 
 
Table 4: Distribution of items indicating the storage practices and distribution of water in pharmaceutical 
industries in Ethiopia, 2013 (N=8). 
 
  Items Response 
Yes; N (%) No; N (%) NA; N (%) 
Presence of a tank for PW storage 8 (100) - - 
A tank being type of sanitary material for PW 7 (87.5) 1 (12.5) - 
Presence of a storage tank for water for injection 5 (62.5) - 3 (37.5) 
Tank being made of sanitary material for WFI 5 (62.5) - 3 (37.5) 
Maintenance of temperature at 70-80°C during storage  5 (62.5) - 3 (37.5) 
Presence of dead legs in the water system 4 (50) 4 (50) - 
PW was kept circulating 7 (87.5) 1 (12.5) - 
Pipes used in the distribution of WFI were ensuring delivery of the 
water up to the point of use 
5 (62.5) - 3 (37.5) 
Pipes were made of sanitary material 4 (50) 1 (12.5) 3 (37.5) 
Water was maintained circulating at 70-80 °C 4 (50) - 4 (50) 
 
Findings of Key Informant Interview 
A total of eight key informants from eight industries 
were interviewed using flexible interview guide. When 
they were asked on overall compliance of the water 
treatment systems of the pharmaceutical industries to 
the WHO GMP principles, majority of the respondents 
mentioned that their water treatment system fulfills 
most of the GMP requirements. On the contrary, one of 
the participants explained the status of an industry as 
follows:  
“…the existing system is an old model which is way 
behind the current GMP requirement. Qualification is 
not done yet for the existing system.” 
Regarding the challenges encountered and actions taken 
during the purification, storage, and distribution of 
WPU, shortage of raw water supply was the major 
challenge mentioned by majority of the participants. As 
a result, different measures were taken by different 
industries including using one’s own groundwater 
source, installation of internal pump and using large 
volume reservoirs. Other challenges stated by some of 
the respondents were increased conductivity of source 
water, decreased adsorption capacity, increased 
concentration of NaOH used for regeneration of IX 
resin, absence of online monitoring system and loop 
circulation system. In some of the pharmaceutical 
industries these resulted in deviation of some 
parameters and failure of microbiological tests. 
However, according to the respondents, appropriate 
actions were taken to resolve some of these challenges. 
This was evident from one of the respondents:  
“The problem of increased conductivity was resolved by 
enhancing the efficiency of the demineralizer and 
galvanization of the water line from the well up to the 
raw water storage tank while decreased adsorption 
capacity of the carbon filter was resolved by changing 
the carbon filter and regeneration of IX resin.” 
Participants were asked to mention the opportunities 
and threats towards implementation of the GMP 
principles for water system. Accordingly, the support of 
the government was mentioned by most of the 
participants to be the main opportunity for the 
industries. These include giving local manufacturers 
priority on the market and allowing tax free imports of 
raw materials and machineries. Further, training 
program from the FMHACA and other organizations 
like GIZ (German Federal Enterprise for International 
Cooperation) were mentioned as opportunities. On the 
other hand, the study participants revealed that erratic 
raw water supply, absence of competent calibration 
laboratories, shortage of foreign currency, and delay 
during import of raw materials and equipment were 
among the main threats for the pharmaceutical 
industries in Ethiopia. 
Finally, participants were asked about their 
recommendations and they suggested, among others, 
continuous training and technical support from different 
stakeholders like FMHACA and professional 
associations, implementation of tighter control by 
regulatory bodies, and stronger University-Industry 
linkages to facilitate training and research & 
development collaborations. 
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CONCLUSION 
According to the results of the study, it has been found 
that the water treatment systems in most of the 
pharmaceutical industries do not fully comply with the 
GMP specifications. With regard to monitoring system, 
almost all the pharmaceutical industries have online and 
offline monitoring systems during production of WPU. 
The storage systems for PW and WFI comply with the 
WHO GMP principles for most of the pharmaceutical 
industries. Similarly, the documentation practice of 
most of the industries was found to be close to the 
standard. On the other hand, the distribution systems of 
some industries did not ensure continuous circulation 
and maintenance of temperature at 70-80 
o
C and the 
validation process in most of the industries was found to 
be poor with respect to the standard. Finally, most of 
the industries indicated that shortage of raw water 
supply, absence of competent calibration laboratories, 
and longer lead time during import of raw materials 
were some of the limiting factors in fulfilling the GMP 
standards. 
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